Helsinn Investment Fund Investor

The Helsinn Investment Fund focuses on privately-owned companies with early stage technologies in Cancer Supportive Care, Cancer Diagnostics and Cancer Therapeutics, among other areas close to Helsinn’s interests such as dermatology, metabolism and gastro-intestinal disease. These technologies range from biotech to pharma, medical devices and food supplements.

As well as these investments, Helsinn International Services, Sarl, has signed collaboration agreements with Centre Scientifique de Monaco and Lyfebulb U.S.

Invests into

Technology: N/A
Industry: Preventive Medicine
Headquarters: Monaco, Principality of Monaco
Founded Date: 2016
Employees Number: 11-50
Funding Status: N/A
Investor Type: Venture Capital
Investment Stage: Early Stage Venture
Number Of Exits: 2

Visit Website
hif@helsinn.com
https://twitter.com/HelsinnGroup
Register and Claim Ownership